Back to Search
Start Over
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
- Source :
-
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 1984 Sep; Vol. 10 (9), pp. 1691-6. - Publication Year :
- 1984
-
Abstract
- Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.
- Subjects :
- Clinical Trials as Topic
Combined Modality Therapy
Dexamethasone therapeutic use
Drug Evaluation
Etanidazole
Humans
Misonidazole analogs & derivatives
Misonidazole therapeutic use
Neoplasms drug therapy
Oxygen physiology
Neoplasms radiotherapy
Nitroimidazoles therapeutic use
Radiation-Sensitizing Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0360-3016
- Volume :
- 10
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- International journal of radiation oncology, biology, physics
- Publication Type :
- Academic Journal
- Accession number :
- 6237083
- Full Text :
- https://doi.org/10.1016/0360-3016(84)90530-3